EDMONTON, Jan. 30 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced results ...
EDMONTON, April 30 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), today announced that the University of Alberta, a major shareholder of the Company, has ...
EDMONTON, AB, May 3 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), today announced its updated corporate strategy. The Company's new strategy will encompass ...
TORONTO and EDMONTON , Dec. 17 /CNW/ - Spectral Diagnostics Inc. (TSX: SDI) and BioMS Medical Corp. (TSX: MS) today announced that BioMS Medical ("BioMS") and a syndicate of investors have invested ...
A successful phase II trial of BioMS Medical Corp.'s (BOMSF.PK) lead compound dirucotide for the treatment of Multiple Sclerosis would undoubtedly give a boost to the biotech share price, but with ...
Eli Lilly and partner BioMS Medical Corp‘s dirucotide has failed a late-stage trial as a potential treatment for multiple sclerosis. Eli Lilly and partner BioMS Medical Corp‘s dirucotide has failed a ...
BioMS Medical Corp. has reported that it has completed the previously-announced licensing and development agreement with Eli Lilly and Company. As part of the agreement, BioMS has received an upfront ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback